ENTRADA THERAPEUTICS, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 13.92 USD | -0.96% |
|
+2.40% | -7.99% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site
Financials (USD)
| Sales 2024 * | 135M | Sales 2025 * | 42.11M | Capitalization | 446M |
|---|---|---|---|---|---|
| Net income 2024 * | -4M | Net income 2025 * | -141M | EV / Sales 2024 * | 2.54 x |
| Net cash position 2024 * | 104M | Net cash position 2025 * | 141M | EV / Sales 2025 * | 7.24 x |
| P/E ratio 2024 * |
-14.2
x | P/E ratio 2025 * |
-3.95
x | Employees | 160 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 82.06% |
More Fundamentals
* Assessed data
More news
Latest transcript on Entrada Therapeutics, Inc.
More recommendations
More press releases
| 1 day | -1.07% | ||
| 1 week | +2.40% | ||
| Current month | +17.17% | ||
| 1 month | +4.56% | ||
| 3 months | -8.23% | ||
| 6 months | -13.81% | ||
| Current year | -7.99% |
1 week
12.92
14.25
1 month
11.8114.25
Current year
11.3517.26
1 year
10.6218.44
3 years
5.1236.85
5 years
5.1236.85
10 years
5.1236.85
| Managers | Title | Age | Since |
|---|---|---|---|
Dipal Doshi
CEO | Chief Executive Officer | 48 | 17-07-31 |
Kory Wentworth
DFI | Director of Finance/CFO | 45 | 20-10-31 |
Nathan Dowden
PSD | President | 54 | 19-11-03 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Peter Kim
BRD | Director/Board Member | 65 | 20-11-30 |
Mary Thistle
BRD | Director/Board Member | 64 | 21-05-03 |
Gina Chapman
BRD | Director/Board Member | 57 | 23-08-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 0 M€ | +3.45% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-09 | 13.88 | -1.17% | 1 290 |
| 24-05-08 | 14.05 | +1.22% | 57,449 |
| 24-05-07 | 13.88 | +2.81% | 44,564 |
| 24-05-06 | 13.5 | +2.58% | 25,808 |
| 24-05-03 | 13.16 | -2.95% | 38,162 |
Delayed Quote Nasdaq, May 09, 2024 at 09:51 am EDT
More quotes
Entrada Therapeutics, Inc. is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a class of medicines, which engages intracellular targets that have long been considered inaccessible. The Companyâs Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient delivery of a range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. Through its proprietary, highly versatile and modular EEV platform (EEV Platform), the Company is building a robust development portfolio of therapeutic candidates. Its first two drug candidates, ENTR-601-44 and VX-670, are in clinical trials. VX-670 for dystrophy type 1 (DM1) is designed to block the triplet repeats in the messenger RNA (mRNA). ENTR-601-44 is in a Phase I clinical trial. The Company also announced the selection of additional clinical candidates within its Duchenne franchise, ENTR-601-45 and ENTR-601-50.
Calendar
12:00am
- Q1 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
14.05
USD
Average target price
21
USD
Spread / Average Target
+49.47%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -7.99% | 446M | |
| +2.68% | 108B | |
| +9.24% | 105B | |
| -0.44% | 23.46B | |
| -14.38% | 21.72B | |
| -7.05% | 18.64B | |
| -38.55% | 17.45B | |
| -7.52% | 17.19B | |
| +6.39% | 13.99B | |
| +35.51% | 12.53B |
- Stock Market
- Equities
- TRDA Stock